title: Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome.
abstract: IL-1 receptor antagonist anakinra is usually highly efficient in Schnitzler syndrome (SS), a rare inflammatory condition associating urticaria, fever, and IgM monoclonal gammopathy. In this study, we aimed to assess lipopolysaccharide (LPS)-induced production of inflammatory cytokines by peripheral blood mononuclear cells (PBMCs) before and after 1 month of anakinra in patients with SS. LPS-induced production of IL-1β, IL-6 and TNFα was assessed by enzyme-linked immunosorbent assay with and without anakinra in vitro, and before and after 1 month (in vivo condition) of treatment in 2 patients with SS. Spontaneous production of IL-1β, IL-6 and TNF-α by PBMCs was similar in the patients and the healthy controls and was almost undetectable. Stimulation with LPS caused a higher release of cytokines from the patients than from the healthy controls. Before in vivo anakinra start, in vitro adjunction of anakinra reduced the high LPS-induced production of IL-1β and TNFα in both patients and of IL-6 in one patient. After 1 month of treatment with anakinra, while the patients had dramatically improved, there was also a marked reduction in LPS-induced cytokines production, which was almost normalized in one patient. This study shows an abnormal LPS-induced inflammatory cytokines production in SS, which can be decreased or even normalized by in vitro and in vivo anakinra.
authors.affiliation: Lille Nord de France University, Department of Internal Medicine and Clinical Immunology, National Reference Center for Rare Autoimmune and Systemic Diseases, Lille, France. david.launay@chru-lille.fr
authors.forename: David
authors.initials: D
authors.lastname: Launay
authors.forename: Virginie
authors.initials: V
authors.lastname: Dutoit-Lefevre
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Faure
authors.forename: Olivier
authors.initials: O
authors.lastname: Robineau
authors.forename: Carine
authors.initials: C
authors.lastname: Hauspie
authors.forename: Vincent
authors.initials: V
authors.lastname: Sobanski
authors.forename: Eric
authors.initials: E
authors.lastname: Hachulla
authors.forename: Myriam
authors.initials: M
authors.lastname: Labalette
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Hatron
authors.forename: Sylvain
authors.initials: S
authors.lastname: Dubucquoi
mesh_terms: D016207:Cytokines / Q000378:metabolism*; D017931:DNA Primers / Q000235:genetics; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000494:pharmacology*; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D008070:Lipopolysaccharides; D060888:Real-Time Polymerase Chain Reaction; D019873:Schnitzler Syndrome / Q000188:drug therapy* / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D016207:Cytokines; D017931:DNA Primers; D053590:Interleukin 1 Receptor Antagonist Protein; D053583:Interleukin-1beta; D015850:Interleukin-6; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha